Koselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1 09 March
ENHERTU® granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer 09 March
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer 09 March
